SCHEMBL10111073

SCHEMBL10111073

COCOc1cc(C)ccc1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
TDP1 Q9NUW8 3/20 0.49
GAA P10253 1/20 0.49
HTT P42858 3/20 0.49
CYP2C9 P11712 2/20 0.49
LMNA P02545 1/20 0.49
ALDH1A1 P00352 2/20 0.45
TTR P02766 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C8 P10632 1/20 0.45
CHRM1 P11229 1/20 0.45
ADRA1A P35348 1/20 0.45
PPARG P37231 1/20 0.45
HTR2B P41595 1/20 0.45
PPARA Q07869 1/20 0.45
SLCO1B3 Q9NPD5 1/20 0.45
CISD1 Q9NZ45 1/20 0.45
SLCO1B1 Q9Y6L6 1/20 0.45
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11890520 0.85 ACHE (0.52) SMN1; SMN2TDP1GAACYP2C9ALDH1A1
SCHEMBL30802160 0.85 ACHE (0.52) SMN1; SMN2TDP1GAACYP2C9ALDH1A1
SCHEMBL12772059 0.83 HPGD (0.50) TSHRSMN1; SMN2GAALMNAALDH1A1
SCHEMBL29601399 0.83 HPGD (0.50) TSHRSMN1; SMN2GAALMNAALDH1A1
SCHEMBL13475556 0.82 TSHR (0.59) TSHRSMN1; SMN2TDP1GAAHTT
SCHEMBL12408754 0.82 ACHE (0.65) SMN1; SMN2TDP1GAACYP2C9ALDH1A1
SCHEMBL12375199 0.82 ACHE (0.65) SMN1; SMN2TDP1GAAHTTCYP2C9
SCHEMBL9901812 0.82 GAA (0.41) TSHRSMN1; SMN2TDP1GAAHTT
SCHEMBL5929495 0.80 TSHR (0.67) TSHRSMN1; SMN2TDP1HTTCYP2C9
SCHEMBL23759950 0.80 CYP3A4 (0.37) TSHRSMN1; SMN2TDP1CYP2C9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9704612-B2 Composition of silver-conjugated compound composite SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-07-11 US disclosed
US-9536633-B2 Metallic composite and composition thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-01-03 US disclosed
US-8778874-B2 Glycopeptide antibiotic monomer derivatives NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2014-07-15 US disclosed
US-20120032121-A1 METALLIC COMPOSITE AND COMPOSITION THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-02-09 US disclosed
US-20100033086-A1 POLYMER COMPOUND AND COMPOSITION CONTAINING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-02-11 US disclosed
US-20100033086-A1 POLYMER COMPOUND AND COMPOSITION CONTAINING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-02-11 US disclosed
EP-2123691-A1 POLYMER COMPOUND AND COMPOSITION CONTAINING THE SAME Sumitomo Chemical Company, Limited (JP) 2009-11-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120032121-A1 METALLIC COMPOSITE AND COMPOSITION THEREOF CDH1, EPCAM, CD4 TSHR 3714/4885SMN1; SMN2 2087/4885TDP1 4138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.